P253 Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: Further insights from Principal Investigators of the ECFS Clinical Trials Network

C.M Sloan,L.J Sherrard,G.G Einarsson,L.J Dupont,S Van Koningsbruggen-Rietschel,N.J Simmonds,D.G Downey

doi:10.1016/s1569-1993(23)00625-2

P253 Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: Further insights from Principal Investigators of the ECFS Clinical Trials Network

C.M Sloan, L.J Sherrard + Show 5 more

https://doi.org/10.1016/s1569-1993(23)00625-2

Copy DOI

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Publication Date: Jun 1, 2023

Affiliation: Queen's University Belfast, KU Leuven, University Hospital Cologne, Imperial College London

#Chronic Airway Infections #Cystic Fibrosis + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Inhaled antibiotics are a pivotal part of management of Pseudomonas aeruginosa (Pa) chronic airway infections in people with Cystic Fibrosis (pwCF). This study aimed to gain further insights into how Principal Investigators (PIs) in the ECFS-Clinical Trials Network (CTN) optimised inhaled antibiotic regimens to manage Pa infections in pwCF.

Full Text